« Back
Home /
MAX-40279 (hemifumarate)

MAX-40279 (hemifumarate)

Item no.	HY-145723B-1ea
Manufacturer	MedChem Express
CASRN	2388506-43-0
Amount	1 ea
Quantity options	100 mg 10 mg 1 ea 25 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Molecules
Specific against	other
Purity	99.56
Citations	[1]Yuguang Wang, et al. Novel Therapeutic Methods. Patent WO2021180032A1.
Smiles	OC(/C=C/C(O)=O)=O.CC1=C(C2=C(C=C(C=C2)F)OC)C3=NC(NC4=CN(C5CCNCC5)N=C4)=NC=C3S1
ECLASS 10.1	32169090
ECLASS 11.0	32169090
UNSPSC	12000000
Shipping Condition	Cool pack
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	COVID-19-immunoregulation
Manufacturer - Targets	FGFR; FLT3
Shipping Temperature	Blue Ice
Storage Conditions	-20°C (Powder, sealed storage, away from moisture)
Molecular Weight	554.59
Product Description	MAX-40279 hemifumarate is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hemifumarate has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032)[1].
Manufacturer - Research Area	Cancer; Inflammation/Immunology
Solubility	DMF: 1.96 mg/mL (ultrasonic; warming; adjust pH to 5 with HCl; heat to 60°C)
Manufacturer - Pathway	Protein Tyrosine Kinase/RTK
Clinical information	Phase 2

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-145723B-1ea-safety-datasheet.pdf